Difference between revisions of "BCG vaccine"
(moved Bacillus Calmette-Guerin (BCG) to Bacillus Calmette-Guerin (BCG, TheraCys): adding trade name) |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | # | + | Also known as Bacille Calmette–Guérin, TheraCys, or TICE BCG. |
| + | |||
| + | ==General information== | ||
| + | Class/mechanism: Live mycobacteria which promote a local acute inflammatory and sub-acute granulomatous reaction with macrophage and leukocyte infiltration in the urothelium and lamina propria of the urinary bladder. This results in a likely T-lymphocyte dependent anti-tumor effect.<ref name="insert">[https://www.vaccineshoppecanada.com/secure/pdfs/ca/immucyst_e.pdf Bacillus Calmette-Guerin (BCG) package insert]</ref><ref>[[Media:Bacilluscalmetteguerin.pdf | Bacillus Calmette-Guerin (BCG) package insert (locally hosted backup)]]</ref> | ||
| + | <br>Route: Intravesicular | ||
| + | <br>Extravasation: n/a | ||
| + | |||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Bladder cancer]] (intravesicular use) | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[https://www.vaccineshoppecanada.com/secure/pdfs/ca/immucyst_e.pdf#page=22 Bacillus Calmette-Guerin (BCG) package insert PDF pages 22-24]<ref name="insert"></ref> | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/bcg.aspx Bacillus Calmette-Guerin (BCG) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bcg.aspx Bacillus Calmette-Guerin (BCG) patient information (Chemocare)]</ref> | ||
| + | *[http://www.uptodate.com/contents/patient-information-bladder-cancer-treatment-non-muscle-invasive-superficial-cancer Patient information about bladder cancer treatment, including BCG (UpToDate)]<ref>[http://www.uptodate.com/contents/patient-information-bladder-cancer-treatment-non-muscle-invasive-superficial-cancer Patient information about bladder cancer treatment, including BCG (UpToDate)]</ref> | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
Revision as of 17:40, 7 October 2012
Also known as Bacille Calmette–Guérin, TheraCys, or TICE BCG.
General information
Class/mechanism: Live mycobacteria which promote a local acute inflammatory and sub-acute granulomatous reaction with macrophage and leukocyte infiltration in the urothelium and lamina propria of the urinary bladder. This results in a likely T-lymphocyte dependent anti-tumor effect.[1][2]
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bladder cancer (intravesicular use)
Patient drug information
- Bacillus Calmette-Guerin (BCG) package insert PDF pages 22-24[1]
- Bacillus Calmette-Guerin (BCG) patient drug information (Chemocare)[3]
- Patient information about bladder cancer treatment, including BCG (UpToDate)[4]